CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia
Acute Myeloid Leukemia, Relapsed, Adult
DRUG: CDIAG regimen
Remission Rate, Remission rate achieved after one-two couses induction therapy by CDIAG regimen, 1 month|Overall survial, It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive., 1 year
Adverse events in hematological system, Record of adverse events in hematological system during and after CDIAG regimen induction, 1 month|Adverse events in other organs or systems, Record of adverse events in other organs or systmes during and after CDIAG regimen induction, 1 month
This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia